-
1
-
-
79551638273
-
Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism
-
Eriksson BI, Quinlan DJ, Eikelboom JW: Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
-
(2011)
Annu Rev Med
, vol.62
, pp. 41-57
-
-
Eriksson, B.I.1
Quinlan, D.J.2
Eikelboom, J.W.3
-
2
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
Eriksson BI, Borris LC, Friedman RJ, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
-
(2008)
N Engl J Med
, vol.358
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
-
3
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
Kakkar AK, Brenner B, Dahl OE, et al: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
-
4
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
Lassen MR, Ageno W, Borris LC, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
-
(2008)
N Engl J Med
, vol.358
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
-
5
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
-
Turpie AGG, Lassen MR, Davidson BL, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.1
Lassen, M.R.2
Davidson, B.L.3
-
6
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
-
7
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
The EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
-
8
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
The EINSTEIN–PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
-
(2012)
N Engl J Med
, vol.366
, pp. 1287-1297
-
-
-
9
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
Mega JL, Braunwald E, Wiviott SD, et al: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
-
(2012)
N Engl J Med
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
-
10
-
-
3042520870
-
Digoxin in the management of cardiovascular disorders
-
Gheorghiade M, Adams KF, Jr, Colucci WS: Digoxin in the management of cardiovascular disorders. Circulation 2004; 109: 2959-2964.
-
(2004)
Circulation
, vol.109
, pp. 2959-2964
-
-
Gheorghiade, M.1
Adams, K.F.2
Colucci, W.S.3
-
11
-
-
0025779484
-
Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
-
Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
-
(1991)
Stroke
, vol.22
, pp. 983-988
-
-
Wolf, P.A.1
Abbott, R.D.2
Kannel, W.B.3
-
12
-
-
0033514320
-
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
-
Fromm MF, Kim RB, Stein CM, et al: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-557.
-
(1999)
Circulation
, vol.99
, pp. 552-557
-
-
Fromm, M.F.1
Kim, R.B.2
Stein, C.M.3
-
13
-
-
0024102997
-
Pharmacokinetic interactions with digoxin
-
Rodin SM, Johnson BF: Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227-244.
-
(1988)
Clin Pharmacokinet
, vol.15
, pp. 227-244
-
-
Rodin, S.M.1
Johnson, B.F.2
-
14
-
-
33646553591
-
The safety of digoxin as a pharmacological treatment of atrial fibrillation
-
Tamargo J, Delpon E, Caballero R: The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf 2006; 5: 453-467.
-
(2006)
Expert Opin Drug Saf
, vol.5
, pp. 453-467
-
-
Tamargo, J.1
Delpon, E.2
Caballero, R.3
-
15
-
-
39049156419
-
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery
-
Howard PA, Barnes BJ: Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery. Ann Pharmacother 2008; 42: 253-258.
-
(2008)
Ann Pharmacother
, vol.42
, pp. 253-258
-
-
Howard, P.A.1
Barnes, B.J.2
-
16
-
-
38849099077
-
Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery
-
Lertsburapa K, White CM, Kluger J, et al: Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008; 135: 405-411.
-
(2008)
J Thorac Cardiovasc Surg
, vol.135
, pp. 405-411
-
-
Lertsburapa, K.1
White, C.M.2
Kluger, J.3
-
17
-
-
33749505716
-
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study
-
Patti G, Chello M, Candura D, et al: Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-1461.
-
(2006)
Circulation
, vol.114
, pp. 1455-1461
-
-
Patti, G.1
Chello, M.2
Candura, D.3
-
18
-
-
0242383181
-
Clinical pharmacokinetics of atorvastatin
-
Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
-
(2003)
Clin Pharmacokinet
, vol.42
, pp. 1141-1160
-
-
Lennernäs, H.1
-
19
-
-
2942705774
-
Safety of statins: Focus on clinical pharmacokinetics and drug interactions
-
Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 suppl 1): III50-III57.
-
(2004)
Circulation
, vol.109
, Issue.23
, pp. III50-III57
-
-
Bellosta, S.1
Paoletti, R.2
Corsini, A.3
-
20
-
-
0034821958
-
Rhabdomyolysis and HMG-CoA reductase inhibitors
-
Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.
-
(2001)
Ann Pharmacother
, vol.35
, pp. 1096-1107
-
-
Omar, M.A.1
Wilson, J.P.2
Cox, T.S.3
-
21
-
-
0036163750
-
FDA adverse event reports on statin-associated rhabdomyolysis
-
Omar MA, Wilson JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295.
-
(2002)
Ann Pharmacother
, vol.36
, pp. 288-295
-
-
Omar, M.A.1
Wilson, J.P.2
-
22
-
-
22844442726
-
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 − an oral, direct Factor Xa inhibitor
-
Perzborn E, Strassburger J, Wilmen A, et al: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 − an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 514-521
-
-
Perzborn, E.1
Strassburger, J.2
Wilmen, A.3
-
23
-
-
78650827771
-
The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor
-
Perzborn E, Roehrig S, Straub A, et al: The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 2011; 10: 61-75.
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 61-75
-
-
Perzborn, E.1
Roehrig, S.2
Straub, A.3
-
24
-
-
25844525489
-
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
-
Kubitza D, Becka M, Voith B, et al: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 412-421
-
-
Kubitza, D.1
Becka, M.2
Voith, B.3
-
25
-
-
29144518504
-
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects
-
Kubitza D, Becka M, Wensing G, et al: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
-
(2005)
Eur J Clin Pharmacol
, vol.61
, pp. 873-880
-
-
Kubitza, D.1
Becka, M.2
Wensing, G.3
-
26
-
-
66449099711
-
Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans
-
Weinz C, Schwarz T, Kubitza D, et al: Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37: 1056-1064.
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 1056-1064
-
-
Weinz, C.1
Schwarz, T.2
Kubitza, D.3
-
28
-
-
0032848316
-
Pglycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil
-
Verschraagen M, Koks CH, Schellens JH, et al: Pglycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40: 301-306.
-
(1999)
Pharmacol Res
, vol.40
, pp. 301-306
-
-
Verschraagen, M.1
Koks, C.H.2
Schellens, J.H.3
-
29
-
-
0031925714
-
Digoxin revisited
-
Li-Saw-Hee FL, Lip GYH: Digoxin revisited. QJM 1998; 91: 259-264.
-
(1998)
QJM
, vol.91
, pp. 259-264
-
-
Li-Saw-Hee, F.L.1
Lip, G.2
-
30
-
-
33846448135
-
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmaco -dynamics of rivaroxaban (BAY 59-7939) in healthy subjects
-
Kubitza D, Becka M, Zuehlsdorf M, et al: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmaco -dynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-226.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 218-226
-
-
Kubitza, D.1
Becka, M.2
Zuehlsdorf, M.3
-
32
-
-
77957699729
-
Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
-
Camm AJ, Kirchhof P, Lip GYH, et al: Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
-
(2010)
Eur Heart J
, vol.31
, pp. 2369-2429
-
-
Camm, A.J.1
Kirchhof, P.2
Lip, G.3
-
33
-
-
84856745317
-
Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines
-
You JJ, Singer DE, Howard PA, et al: Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 suppl): e531S-e575S.
-
(2012)
Chest
, vol.141
, Issue.2
, pp. e531S-e575S
-
-
You, J.J.1
Singer, D.E.2
Howard, P.A.3
-
34
-
-
34250901454
-
Latest medical treatment strategies for venous thrombo -embolism
-
McRae SJ, Eikelboom JW: Latest medical treatment strategies for venous thrombo -embolism. Expert Opin Pharmacother 2007; 8: 1221-1233.
-
(2007)
Expert Opin Pharmacother
, vol.8
, pp. 1221-1233
-
-
McRae, S.J.1
Eikelboom, J.W.2
-
35
-
-
79959522836
-
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban
-
Gnoth MJ, Buetehorn U, Muenster U, et al: In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011; 338: 372-380.
-
(2011)
J Pharmacol Exp Ther
, vol.338
, pp. 372-380
-
-
Gnoth, M.J.1
Buetehorn, U.2
Muenster, U.3
-
36
-
-
0023189084
-
Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations
-
Eisendrath SJ, Sweeney MA: Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987; 144: 506-507.
-
(1987)
Am J Psychiatry
, vol.144
, pp. 506-507
-
-
Eisendrath, S.J.1
Sweeney, M.A.2
-
38
-
-
3242759673
-
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers
-
Sarich TC, Schützer KM, Wollbratt M, et al: No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004; 44: 935-941.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 935-941
-
-
Sarich, T.C.1
Schützer, K.M.2
Wollbratt, M.3
-
39
-
-
3242742755
-
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran
-
Sarich TC, Schützer KM, Dorani H, et al: No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004; 44: 928-934.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 928-934
-
-
Sarich, T.C.1
Schützer, K.M.2
Dorani, H.3
-
40
-
-
0036394274
-
Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers
-
Mant T, Fournié P, Ollier C, et al: Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41(suppl 2): 39-45.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 39-45
-
-
Mant, T.1
Fournié, P.2
Ollier, C.3
|